about
Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin.Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinomaLeucine-rich alpha 2 glycoprotein promotes Th17 differentiation and collagen-induced arthritis in mice through enhancement of TGF-β-Smad2 signaling in naïve helper T cells.SOCS1, a Negative Regulator of Cytokine Signals and TLR Responses, in Human Liver Diseases.Regulation of cytokine signaling by SOCS family molecules.Annexin A4 induces platinum resistance in a chloride-and calcium-dependent mannerPeriostin facilitates skin sclerosis via PI3K/Akt dependent mechanism in a mouse model of scleroderma.Leucine-rich α-2-glycoprotein promotes TGFβ1-mediated growth suppression in the Lewis lung carcinoma cell linesGene therapy with SOCS1 for gastric cancer induces G2/M arrest and has an antitumour effect on peritoneal carcinomatosis.Interleukin-6 Deficiency Does Not Affect Motor Neuron Disease Caused by Superoxide Dismutase 1 Mutation.Sputum Leucine-Rich Alpha-2 Glycoprotein as a Marker of Airway Inflammation in Asthma.CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.Cell surface localization of importin α1/KPNA2 affects cancer cell proliferation by regulating FGF1 signalling.Similar protein expression profiles of ovarian and endometrial high-grade serous carcinomas.Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma.ifn-γ-dependent secretion of IL-10 from Th1 cells and microglia/macrophages contributes to functional recovery after spinal cord injuryLeucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis.Suppressor of cytokine signaling-1 gene therapy induces potent antitumor effect in patient-derived esophageal squamous cell carcinoma xenograft mice.Suppressor of cytokine signalling-1 induces significant preclinical antitumor effect in malignant melanoma cells.Salt-inducible kinase 3 deficiency exacerbates lipopolysaccharide-induced endotoxin shock accompanied by increased levels of pro-inflammatory molecules in mice.Periostin accelerates human malignant melanoma progression by modifying the melanoma microenvironment.Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A.Molecular mechanism underlying the antiproliferative effect of suppressor of cytokine signaling-1 in non-small-cell lung cancer cells.New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis.Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer.Antiproliferative effect of SOCS-1 through the suppression of STAT3 and p38 MAPK activation in gastric cancer cells.Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma.Luteolin, a flavonoid, inhibits CD40 ligand expression by activated human basophils.SOCS-2 interferes with myotube formation and potentiates osteoblast differentiation through upregulation of JunB in C2C12 cells.Suppressor of cytokine signaling 1 suppresses muscle differentiation through modulation of IGF-I receptor signal transduction.Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines.Green tea polyphenol epigallocatechin gallate inhibits cell signaling by inducing SOCS1 gene expression.Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer.Flavonoids such as luteolin, fisetin and apigenin are inhibitors of interleukin-4 and interleukin-13 production by activated human basophils.SOCS1 Gene Therapy Improves Radiosensitivity and Enhances Irradiation-Induced DNA Damage in Esophageal Squamous Cell Carcinoma.Leucine-rich α-2 glycoprotein promotes lung fibrosis by modulating TGF-β signaling in fibroblasts.Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake.Osteoblast differentiation is impaired in SOCS-1-deficient mice.SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling.
P50
Q33481792-4AE39FA1-4F94-4368-85E9-9379AED97009Q33648638-6883D0F9-3E85-4F43-AE0F-FA326B42A3BDQ33802290-AD667BB9-69A1-4D30-97DC-9A7D6C8D7725Q34127568-48AC5705-16E6-4260-9176-CD709543C29BQ34279652-89AE8D3D-AC85-455E-A6FF-5FE616C0CB6CQ34365873-D9D9A1A1-B0F9-4B93-8688-E6CB69AE3E34Q34388282-539C5BF5-EEEA-44AD-A3F4-F9E68447FCCDQ35793694-7300F6D3-B941-4B1B-8CA8-E876DD3C9B8AQ35909650-211E3F82-EF5C-486B-A076-60F1824884C2Q35986943-0FA6EF7E-E021-4254-A31C-9D1D696A8C37Q36128008-9375533C-A4FF-4B50-AF22-F975E720F71BQ36262941-0B6FA11A-EF8C-4C66-A173-32C536C88F92Q36591378-62403379-3B1A-4561-B2E8-2A9C87912BCEQ36662048-BAC98ABF-1A1E-4751-8C43-C6D915758E32Q37061381-0C687512-FEA6-440A-AFCC-D5A8DE9F7B00Q37062017-5C462A88-80EC-442F-B973-97C3B1237C73Q37523499-A6165394-C5BD-4410-B4F0-95AB110EAE46Q38715093-599DBBFB-1454-4A92-8A1B-A140610010F6Q38853116-04F2F4B9-8FA5-4908-A048-CACA303D0650Q38916736-2DC0A7EB-B98C-4356-9968-C80030011AB5Q39011153-604AB218-D458-43B6-BA22-ADEF5B91267AQ39073167-8F44F2A1-7E48-4311-9113-70F69624C439Q39107722-6AF5055B-2681-4ABB-A7F8-89C32E92CDF9Q39146365-C26DB3EB-E92B-4349-B595-B4904DBCE79FQ39325995-FE61247A-BFEC-4942-9159-22F0006BA7D8Q39441167-7F77E473-AB1C-4691-90FE-27F0A40CE6F8Q39643717-17B614C7-C5F3-45D0-82ED-4988A48DD5A4Q40294730-16404D64-EB28-4114-ADCA-C78EDC0FBE01Q40328324-4FC3AD65-84D0-437F-AE2C-AC8EE0E388EDQ40459260-328C81CC-902D-47CD-8FEC-8F517793F21EQ40522793-083FC050-C3F2-4F5E-B74B-DE7D3D2B674CQ43147193-D4E54EC5-196D-4F4E-B46B-C518CFCD0E3AQ43784891-DD3D18C0-FFFC-488B-97BF-446AA985A01EQ44903540-352923CC-0C02-4337-949B-AA457141A008Q45873282-ADE7F4BA-6C4B-4273-BD66-1E1DACD02EC2Q47115506-A2912FE1-B46B-43D1-9EA9-6CB504CB3C90Q47750583-BFEE4CB9-07B4-43EB-AF4E-84BC3E464CEAQ49541303-4F8568E7-A22B-4093-9817-5CB32A3C3ED7Q52571885-542BE590-37D5-4D5F-A10E-6929B7511931Q52603322-063D8DD0-8879-4C99-B4CB-B02A1A067E26
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Minoru Fujimoto
@ast
Minoru Fujimoto
@en
Minoru Fujimoto
@es
Minoru Fujimoto
@nl
type
label
Minoru Fujimoto
@ast
Minoru Fujimoto
@en
Minoru Fujimoto
@es
Minoru Fujimoto
@nl
prefLabel
Minoru Fujimoto
@ast
Minoru Fujimoto
@en
Minoru Fujimoto
@es
Minoru Fujimoto
@nl
P106
P1153
35329492000
P31
P496
0000-0002-6390-8863